Every Form 4 that Mereo BioPharma Group plc American (MREO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MREO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MREO filings page.
Jacquet Pierre reported acquisition or exercise transactions in this Form 4 filing.
Mereo BioPharma Group plc director Pierre Jacquet reported equity awards rather than open‑market trades. He received share options for 66,000 shares at a price of $0.00 per share and 106,848 deferred restricted stock units, both recorded as direct beneficial ownership.
The options vest in substantially equal monthly installments over one year from the February 26, 2026 grant date. The deferred restricted stock units are granted in lieu of annual cash compensation, vest monthly over the following plan year, and are generally settled in American Depositary Shares about 180 days after separation of service. Each ADS represents five ordinary shares.
Mereo BioPharma Group plc director Marc J. Yoskowitz reported equity compensation awards. He received share options covering 66,000 shares at an exercise price of $0.0000 per share, classified as a grant or award acquisition.
He was also granted 96,163 deferred restricted stock units, which are provided in the form of American Depositary Shares instead of annual cash compensation. The options vest in substantially equal monthly installments over one year from the February 26, 2026 grant date, while the deferred restricted stock units vest in substantially equal monthly installments over the plan year and are generally settled in ADSs 180 days after separation of service.
Shames Daniel reported acquisition or exercise transactions in this Form 4 filing.
Mereo BioPharma Group plc director Daniel Shames reported receiving new equity awards. On February 26, 2026, he was granted 66,000 share options and 96,163 deferred restricted stock units as compensation. The options vest in substantially equal monthly installments over one year from the grant date.
The deferred restricted stock units are granted in the form of American Depositary Shares instead of annual cash compensation for non-executive directors and also vest in substantially equal monthly installments over the plan year. Each ADS represents five ordinary shares of Mereo BioPharma Group plc.
Ekblom Anders reported acquisition or exercise transactions in this Form 4 filing.
Mereo BioPharma Group plc director Anders Ekblom reported equity awards that increase his potential ownership stake. He received share options for 66,000 shares at a price of $0.0000 per share and 133,560 deferred restricted stock units, both granted on February 26, 2026.
The options vest in substantially equal monthly installments over one year from the grant date. The deferred restricted stock units were elected in lieu of annual cash compensation and also vest in substantially equal monthly installments over the plan year, with settlement in American Depositary Shares, where each ADS represents five ordinary shares, generally 180 days after separation of service.
Mereo BioPharma Group plc director Jeremy Bender reported equity awards rather than open-market trades. On February 26, 2026, he received share options for 66,000 shares at a price of $0.00 per share, vesting in substantially equal monthly installments over one year from the grant date.
He also acquired 117,533 deferred restricted stock units, granted in lieu of annual cash compensation, which vest in substantially equal monthly installments over the plan year following the grant date. Each American Depositary Share represents five ordinary shares, and payment of these deferred units in ADSs will generally occur 180 days after separation of service.
PAKIANATHAN DEEPIKA reported acquisition or exercise transactions in this Form 4 filing.
Mereo BioPharma Group plc director Deepika Pakianathan was granted share options covering 66,000 shares on February 26, 2026. The options have a right to buy the company’s shares at a price of $0.0000 per share.
The grant vests in substantially equal monthly installments over one year from the February 26, 2026 grant date, meaning portions of the award become exercisable each month during that period.
Jenkins Annalisa reported acquisition or exercise transactions in this Form 4 filing.
Mereo BioPharma Group director Annalisa Jenkins received new equity-based compensation awards. She was granted 66,000 share options with a right to buy shares at no initial cost and 106,848 deferred restricted stock units, both dated February 26, 2026.
The share options vest in substantially equal monthly installments over one year from the grant date. The deferred restricted stock units were elected in lieu of annual cash compensation, vest monthly over the following plan year, and are generally settled in American Depositary Shares about 180 days after service ends.
WYZGA MICHAEL S reported acquisition or exercise transactions in this Form 4 filing.
Mereo BioPharma Group plc director Michael S. Wyzga reported receiving a grant of 66,000 share options on February 26, 2026. These options are a right to buy shares and were awarded for no cash payment at grant. The award vests in substantially equal monthly installments over one year from the February 26, 2026 grant date. Each American Depositary Share represents five ordinary shares of the company.
Mereo BioPharma Group plc granted new share options to Chief Scientific Officer John A. Lewicki on February 1, 2026. The awards cover 139,913 share options with a $0.44 exercise price, 46,637 share options with a $1.00 exercise price, and 145,000 share options with a $0.44 exercise price, all over American Depositary Shares.
For the 139,913 options, 25% of the underlying shares vest on February 1, 2027, with the rest vesting in equal monthly installments over the following three years. The 145,000 options vest in substantially equal monthly installments over one year from the February 1, 2026 grant date. Each ADS represents five ordinary shares of Mereo BioPharma Group plc.
Mereo BioPharma Group plc reported that officer Alexandra Hughes-Wilson received new share option grants on February 1, 2026. The awards cover 183,750 American Depositary Shares (ADS) at an exercise price of $0.44, 61,250 ADS at $1.00, and 195,000 ADS at $0.44.
For the 183,750-ADS option, 25% vests on February 1, 2027, with the rest vesting in equal monthly installments over the next three years. The 195,000-ADS option vests in substantially equal monthly installments over one year from the February 1, 2026 grant date. Each ADS represents five ordinary shares of Mereo BioPharma.
Mereo BioPharma Group plc reported that its General Counsel, Sermon Charles, received new share option awards on February 1, 2026. These are derivative securities giving the right to buy American Depositary Shares (ADS) at preset exercise prices.
The grants include options over 315,750 ADS at $0.44, 105,250 ADS at $1.00, and 295,000 ADS at $0.44, all expiring on February 1, 2036. One grant vests 25% on February 1, 2027 with the remainder vesting monthly over three years, while another vests in substantially equal monthly installments over one year from the grant date. Each ADS represents five ordinary shares.
Mereo BioPharma Group plc reported that Chief Executive Officer and director Denise Scots-Knight received new stock option awards on February 1, 2026. She was granted options to buy 1,035,000 American Depositary Shares at $0.44, 345,000 at $1.00, and 480,000 at $0.44, all held directly.
For the 1,035,000-share grant, 25% will vest and become exercisable on February 1, 2027, with the balance vesting in equal monthly installments over the following three years. The 480,000-share grant vests in substantially equal monthly installments over one year from the February 1, 2026 grant date. Each American Depositary Share represents five ordinary shares of the company.
Mereo BioPharma Group plc reported that its Chief Financial Officer, Christine Fox, received grants of share options on February 1, 2026. These derivative awards give her the right to buy 315,750 American Depositary Shares at an exercise price of $0.44, 105,250 ADS at $1.00, and 280,000 ADS at $0.44.
For the 315,750-option grant, 25% of the underlying shares vest and become exercisable on February 1, 2027, with the rest vesting in equal monthly installments over the following three years. The 280,000-option grant vests in substantially equal monthly installments over one year from the February 1, 2026 grant date. Each ADS represents five ordinary shares of Mereo BioPharma.